Weight Loss Injections in Australia: What to Know Before You Ask Your GP

The short version

• They are real and widely used: GLP-1 medicines such as Ozempic, Wegovy and Mounjaro are TGA-approved in Australia for specific uses, and demand is huge.
• The catch: as of mid-2026 none is PBS-subsidised for weight loss alone, so most people pay the full private price.
• The honest advice: these are prescription medicines with side effects and a weight-regain risk. The right first step is a GP conversation, not an online order.

If this is on your mind, you are not alone, and you are in good company. Weight loss injections have become one of the most talked about health topics in Australia, and it is easy to feel both curious and overwhelmed. This article is general information, not medical advice. It is here to help you walk into your doctor’s appointment informed, whatever you decide afterwards.

Why everyone is talking about these injections

The story starts with a genuine surprise. Medicines first developed to treat type 2 diabetes turned out to produce significant weight loss in the people taking them. Demand grew quickly, and governments, insurers and the health system have been catching up ever since.

It is worth saying plainly that weight is personal, and the way we talk about it has changed. These injections have shifted the conversation away from blame and towards treatment, which many people find a relief. You might feel hopeful, uncertain or a mix of both. That is okay.

What matters is that the conversation has moved on, and so has the research. If you are curious whether these medicines could help you, that is a reasonable question, not an unreasonable one.

What they actually are

The injections doing the rounds belong to a family called GLP-1 medicines. They mimic a hormone your body already makes, one that helps regulate appetite, so you feel fuller sooner after eating and the feeling lasts longer.

The names you will hear most often in Australia are semaglutide, sold as Ozempic and Wegovy, and tirzepatide, sold as Mounjaro. They are different medicines with different approvals, and they are not interchangeable. That is why the specific product matters less than the conversation you have with your doctor about which one, if any, fits your situation.

Who they are approved for: the honest map

Approvals in Australia are set by the Therapeutic Goods Administration, and they differ by product. The map below is as reported at the time of writing, so please check the current TGA information before relying on it.

Ozempic is approved and PBS-subsidised for type 2 diabetes. Its use for weight loss is off-label, meaning it is not approved or subsidised for that purpose.

Wegovy is approved for weight management, generally for people with a body mass index of 30 or over, or 27 or over with a weight-related condition. As of mid-2026 it was not yet PBS-subsidised, though a limited future listing was still being negotiated.

Mounjaro is approved for type 2 diabetes and for weight management, but it has remained a private-only medicine after listing negotiations broke down.

One more thing worth knowing: compounded versions of these medicines were banned in Australia in 2024. That means the approved branded products are the only legal ones, and anything offered as a cheap alternative should be treated with real caution.

The PBS reality and what it costs

Here is the honest financial picture. As of mid-2026, none of these medicines is PBS-subsidised for weight loss on its own. Wegovy’s limited listing was still being negotiated, and Mounjaro remained private. What that means in practice is that most people pay the full price themselves.

Private costs run to a few hundred dollars a month, depending on the medicine and the dose. Exact prices move, so treat that as an order of magnitude and check current pricing before you commit. It is an ongoing cost, not a one-off, and it shapes how long you can realistically stay on the medicine.

What the medicines do not do

It helps to be clear about limits, because the marketing can blur them.

These are not a free pass. The weight can return when the medicine stops, particularly if eating and activity habits have not changed in the meantime. There is also a genuine question about losing muscle along with fat, which is why the focus on movement matters so much.

Common side effects include nausea and digestive upset. For many people these settle, but they can be significant, and they are worth discussing with your doctor before you start, not just after.

The evidence-based foundation of any weight management plan is still movement and muscle. The heart guidelines explain how much exercise matters for health, and the physiologist-backed guide to at-home exercises is a good place to start if you are not sure what to do. These medicines tend to work best alongside that foundation, not instead of it.

How to raise it with your GP

Bringing it up can feel awkward, but it does not need to be. Your GP has heard this question many times, and a responsible doctor would rather you ask than order something online.

Be ready to talk about your medical history, any medicines you already take, and what you have tried before. That context helps the doctor work out whether a GLP-1 medicine is appropriate for you, which risks are relevant, and what to expect on cost and duration.

A careful GP will not simply hand you a script. They should explain the options, the side effects and the financial reality, and set expectations honestly. If a conversation feels rushed, it is fair to ask for more time or a follow-up appointment.

One red flag worth naming: buying these medicines from unregulated online sellers, or from anyone offering them without a proper assessment, is genuinely risky. The approved branded products are the only legal ones in Australia, and a prescription exists for a reason.

The first appointment is the one that matters

These medicines have changed the conversation about weight, and for the right person, under proper medical care, they can genuinely help. But they are prescription medicines with real limits, and the decision is not one to make alone.

The first appointment is the one that matters. Book it, take this article with you if it helps, and let the conversation start there. Whatever you decide, you will have made the decision with your doctor, and that is the safest place to make it.

Sources: Therapeutic Goods Administration (TGA) – consumer medicine information for semaglutide and tirzepatide · healthdirect Australia / PBS – how GLP-1 medicines are approved, listed and prescribed in Australia · Australian Government health news (as reported mid-2026) – the PBS listing debate for weight-loss medicines